Physician profile
Benjamin J Barrick
NPI 1659718427
$2,806.92
in general payments reported to CMS, 2019-2025
31 companies · $498 in 2025
The $498 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $206 · 2021: $330 · 2022: $304 · 2023: $447 · 2024: $669 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.68 |
| Education | $349.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $721.76 | 2020-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $334.68 | 2019-2025 | |
| Lilly USA, LLC | $261.65 | 2019-2025 | Ebglyss, Taltz |
| Incyte Corporation | $220.82 | 2021-2025 | Opzelura |
| Amgen INC. | $143.45 | 2021-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $136.23 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $121.49 | 2021-2024 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $102.18 | 2022-2025 | Sotyktu |
| Ucb, INC. | $93.11 | 2024 | Bimzelx |
| Genzyme Corporation | $79.61 | 2019-2024 | |
| Pfizer INC. | $75.58 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.74 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Leo Pharma INC. | $48.67 | 2019-2024 | Adbry |
| Celgene Corporation | $48.30 | 2019 | |
| Almirall LLC | $41.18 | 2025 | Klisyri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $31.42 | 2025 | Sofdra |
| Organogenesis INC. | $26.70 | 2025 | Affinity |
| Strata Skin Sciences, INC. | $26.69 | 2022-2025 | Xtrac |
| Mallinckrodt Hospital Products INC. | $25.21 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $25.09 | 2024 | Libtayo |
| Misonix INC | $23.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.87 | 2022 | |
| Smith+Nephew, INC. | $20.05 | 2025 | Collagenase Santyl |
| Cipher Pharmaceuticals US LLC | $16.10 | 2025 | Spinosad, Natroba |
| Aclaris Therapeutics, INC. | $15.41 | 2019 | |
| Biofrontera INC. | $15.30 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mission Pharmacal Company | $14.52 | 2020 | |
| Journey Medical Corporation | $14.25 | 2024 | |
| Dusa Pharmaceuticals, INC. | $14.05 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.71 | 2019 | |
| Novum Pharma, LLC | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Barrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.